Personalized treatment approach for HER2-positive metastatic breast cancer

Area of Science:

• Oncology
• Medical Research

Background:

• Breast cancer (BC) is a significant global health concern, particularly HER2-positive subtypes, which historically had poorer prognoses.
• Targeted therapies such as trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have transformed the treatment landscape for HER2-positive metastatic breast cancer (MBC).

Purpose of the Study:

• To review current insights into managing HER2-positive metastatic breast cancer (MBC) patients who achieve sustained responses to anti-HER2 therapies.
• To explore emerging strategies, including immunotherapy, locoregional therapies, and liquid biopsies, for enhancing long-term treatment efficacy and patient outcomes.

Main Methods:

• Literature review focusing on clinical advancements and research in HER2-positive metastatic breast cancer treatment.
• Analysis of personalized medicine approaches and novel therapeutic modalities impacting patient response and prognosis.

Main Results:

• Targeted anti-HER2 therapies have significantly improved outcomes for HER2-positive MBC, but treatment resistance is a key limitation.
• Personalized treatment strategies, incorporating tumor characteristics, are crucial for optimizing patient response and survival.
• Recent breakthroughs in immunotherapy, locoregional therapy, and liquid biopsy offer promising avenues for increasing the number of long-term responders.

Conclusions:

• Personalized approaches have demonstrably improved outcomes for HER2-positive MBC.
• Continued research into novel treatments and biomarkers is essential for further enhancing long-term response rates and patient prognoses.
• These advancements hold the potential to guide future clinical practice in breast cancer management.